RE:RE:RE:RE:RE:Regarding the transcript…lots of good & great stuffHello Westcoast and this is an exerpt from a document that I was able to obtain through a friend through the Hong Kong securities.
Originally AN was going to run the phase 3 trial in 2022 as this was stated in their original documents from Hong Kong.
We received the approval from the NMPA in February 2019 for our initiation of an open-label, randomized, multi-center, global phase III clinical trial for AN1004 in combination with paclitaxel in patients with HR+/HER2- mBC in China. We initiated a bridging trial in China in March 2021 to assess the safety and tolerability of AN1004 in combination with paclitaxel for the Chinese patient population with HR+/HER2- mBC. We plan to initiate Phase III clinical trial in China in the first half of 2022.